Morning Buzz: Versar (VSR), Clean Diesel Technologies (CDTI), Tetraphase Pharmaceuticals (TTPH), Herbalife (HLF), FuelCell Energy (FCEL)

Versar Inc. (VSR) shares are currently printing a large uptick, gaining 10% from the previous close. The company announced today that it has been awarded $5.1M chemical splash protective suit framework contract from the Department for International Development of the U.K. Government. These chemical splash protective suits will be distributed in support of the emergency response to the Ebola outbreak.

Tony Otten, CEO of Versar said, “We are proud to provide support to the Department for International Development. This award illustrates the valuable contributions of our emergency response manufacturing facility…”

Versar shares recently gained $0.31 to $3.35. The stock is down more than 37.45% year-over-year and has lost roughly 37.06% year-to-date. In the past 52 weeks, shares of Springfield, Virginia-based company have traded between a low of $2.69 and a high of $7.84.

Versar Inc., which closed Monday at $3.04, has a total market cap of $29.53M.

Shares of Clean Diesel Technologies (CDTI) surged 9% to $3.45 in pre-market trading Tuesday following a press release stating the company announced today new proprietary technology to replace costly use of platinum group and rare earth metals in catalytic converters. CDTI has been granted the first two of a family of patents for Spinel™, a proprietary clean emissions exhaust technology that will dramatically reduce the cost of attaining more stringent clean air standards.

In other CDTI news, the company today said it has raised approximately $4.4 million in gross proceeds through an offering of common stock and warrants to a single institutional investor. Net proceeds from the sale of the shares and warrants, which CDTI expects to close on November 7, will total approximately $3.8 million.

Clean Diesel Technologies is up $0.24 to $3.41 in pre-market trading today. On valuation-measures, shares of CDTI have a t-12 price/sale and mrq/price-book ratio of 0.71 and 4.04, respectively. T-12 profit margin is (15.81%), while EPS registers at ($0.85). The company has a market cap of $39.35M and a median Wall Street price target of $3.75 with a high target of $3.75.

On trading-measure, CDTI has a beta of 2.30 and a short float of 3.98%. In the last 12 months, shares of Oxnard, California-based company have traded between a low of $1.33 and a high of $7.39 with the 50-day MA and 200-day MA located at $1.83 and $2.30 levels, respectively.

CDTI currently prints a one year return of about 126.43%, and a ytd return of around 111.33%.

Investment analysts at Wedbush initiated coverage on shares of Tetraphase Pharmaceuticals, Inc. (TTPH) in a note issued to investors on Tuesday. The firm set an ‘Outperform’ rating and a $31.00 price target on the stock. The firm’s price target would suggest a potential upside of 22% from the stock’s current price.

Tetraphase shares recently gained $1.90 to $25.39. In the past 52 weeks, the Watertown, Massachusetts-based biopharmaceutical company has traded between a low of $8.01 and a high of $26.34, which is almost 228.83% above that low price.

TTPH is up more than 92.23% year-over-year and has gained roughly 73.74% year-to-date.

Shares of Herbalife Ltd. (HLF) plunged nearly 15% to $47.58 in pre-market trading after the nutrition company said its revs and adjusted Q3 EPS growth missed the Street’s estimates. HLF reported a Q3 profit of $0.13 per share, down 92% from $1.32 per share, y/y.

Following the company’s disappointing 3Q results and weak outlook, SunTrust downgraded the name to ‘Neutral’ from ‘Buy’, citing visibility concerns that include recruitment weakness and plans to roll out 12-month qualification globally in 2015. The firm also cut its 12-month base case HLF estimate to $55 from $75.

Herbalife Ltd. shares are currently priced at 10.43x this year’s forecasted earnings compared to the industry’s 16.88x earnings multiple. Ticker has a PEG and forward P/E ratio of 0.62 and 7.74, respectively. Price/sales for the same period is 1.02 while EPS is $4.51. Currently there are 4 analysts that rate HLF a ‘Buy’, while 2 rate it a ‘Hold’. No analyst rates it a ‘Sell’. HLF has a median Wall Street price target of $84.50 with a high target of $110.00.

Shares are down nearly 11% year-over-year ; and 28.65% year-to-date.

FuelCell Energy Inc. (FCEL) is higher by approximately 4% to $2.27 this morning after the company announced the sale of six fuel cell modules totaling 8.4 megawatts (MW) to South Korean partner POSCO Energy.

“We are experiencing strong demand in South Korea for fuel cell parks to supply ultra-clean power efficiently and continuously to the electric grid,” said Jung-Gon Kim, Senior VP of POSCO Energy.

FCEL said the fuel cell component manufacturing building in Pohang, South Korea is completed and is currently being outfitted with production equipment and manufacturing is expected to commence in mid-2015.

FuelCell closed Monday at $2.19. The company has a total market cap of $634.15M.

Be the first to comment

Leave a Reply

Your email address will not be published.


*